Lifeward Ltd Signs $9 Million Strategic Deal with Oramed Pharmaceuticals
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 13 Jan 26
Source: NASDAQ.COM
Lifeward Ltd shares rose 9.72% as it crossed above the 5-day SMA, reflecting strong investor interest.
The company has signed a strategic deal with Oramed Pharmaceuticals, which includes a $9 million investment and a transfer of Oramed's Protein Oral Drug delivery technology. This agreement will grant Oramed a 49.9% ownership interest in Lifeward, enhancing its market influence. Additionally, Lifeward will issue $10 million in convertible notes, further solidifying the partnership.
This strategic collaboration is expected to significantly boost Lifeward's market position and investor confidence, as reflected in the positive market reaction.
Analyst Views on LFWD
Wall Street analysts forecast LFWD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LFWD is 4.50 USD with a low forecast of 4.50 USD and a high forecast of 4.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.620
Low
4.50
Averages
4.50
High
4.50
Current: 0.620
Low
4.50
Averages
4.50
High
4.50
About LFWD
Lifeward Ltd, formerly known as ReWalk Robotics Ltd, is a medical device company. The Company is engaged in designing, developing, and commercializing exoskeletons that allow individuals with mobility impairments or other medical conditions the ability to stand and walk again. The Company offers an exoskeleton that uses its tilt-sensor technology and an onboard computer and motion sensors to drive motorized legs that power movement. Lifeward designs are intended for people with paraplegia, a spinal cord injury resulting in complete or incomplete paralysis of the legs, having the use of their upper bodies and arms. The Company offers multiple products: ReWalk Personal, ReStore Exo-Suit, MYOLYN FES Cycling, and AlterG Anti-Gravity Systems. ReWalk Personal is designed for everyday use by paraplegic individuals at home and in their communities and is custom-fitted for each user. Lifeward Rehabilitation products are for use by paraplegia patients in the clinical rehabilitation environment.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
